- Home
- CYTK
as 12-20-2024 4:00pm EST
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
| Founded: | 1997 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 6.0B | IPO Year: | 2004 |
| Target Price: | $84.07 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Buy | Number of Analysts: | 16 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.38 | EPS Growth: | N/A |
| 52 Week Low/High: | $43.21 - $110.25 | Next Earning Date: | 11-06-2024 |
| Revenue: | $3,219,000 | Revenue Growth: | -58.81% |
| Revenue Growth (this year): | -18.87% | Revenue Growth (next year): | 795.25% |
Stock Insider Trading Activity of Cytokinetics Incorporated (CYTK)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| WIERENGA WENDALL | CYTK | Director | Dec 16 '24 | Sell | $48.61 | 742 | $36,068.62 | 24,559 | |
| HENDERSON JOHN T | CYTK | Director | Dec 11 '24 | Sell | $50.42 | 1,780 | $89,747.60 | 38,461 | |
| Malik Fady Ibraham | CYTK | EVP Research & Development | Dec 10 '24 | Sell | $50.64 | 7,300 | $369,639.00 | 116,071 | |
| Blum Robert I | CYTK | President & CEO | Dec 2 '24 | Sell | $50.76 | 5,000 | $253,800.00 | 397,678 | |
| WIERENGA WENDALL | CYTK | Director | Nov 25 '24 | Sell | $50.00 | 742 | $37,100.00 | 24,559 | |
| Blum Robert I | CYTK | President & CEO | Nov 18 '24 | Sell | $50.55 | 5,000 | $252,750.00 | 397,678 | |
| Malik Fady Ibraham | CYTK | EVP Research & Development | Nov 12 '24 | Sell | $58.48 | 6,342 | $370,880.16 | 116,071 | |
| Blum Robert I | CYTK | President & CEO | Nov 1 '24 | Sell | $51.63 | 5,000 | $258,150.00 | 397,678 | |
| Malik Fady Ibraham | CYTK | EVP Research & Development | Oct 30 '24 | Sell | $51.92 | 7,300 | $378,930.00 | 116,071 | |
| WIERENGA WENDALL | CYTK | Director | Oct 28 '24 | Sell | $52.25 | 4,452 | $232,617.00 | 24,559 |
Latest Cytokinetics Incorporated News
CYTK Breaking Stock News: Dive into CYTK Ticker-Specific Updates for Smart Investing
Motley Fool
a day ago
Why Cytokinetics Stock Was a Nearly 5% Winner Today
MT Newswires
2 days ago
Cytokinetics Says Sanofi Acquiring Rights for Aficamten in Greater China
GlobeNewswire
2 days ago
Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China
Simply Wall St.
3 days ago
Calculating The Fair Value Of Cytokinetics, Incorporated (NASDAQ:CYTK)
MT Newswires
4 days ago
RBC Raises Price Target on Cytokinetics to $82 From $80, Keeps Outperform, Speculative Risk
Argus Research
4 days ago
CYTK: Lowering target price to $50.00
Argus Research
11 days ago
CYTK: Rating increased to a HOLD
MT Newswires
11 days ago
Cytokinetics Insider Sold Shares Worth $369,639, According to a Recent SEC Filing
Compare CYTK vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CYTK Cytokinetics Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.